Academic Journal
View in EDS
PDF Full Text
HTML Full Text

Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer.

Bibliographic Details
Title: Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer.
Authors: Petrić T; Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia., Sabol M; Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia.
Source: International journal of molecular sciences [Int J Mol Sci] 2023 Mar 10; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 10.
Publication Type: Journal Article; Review
Language: English
Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
Imprint Name(s): Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms: Spheroids, Cellular*/metabolism , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/metabolism, Male ; Humans ; Extracellular Matrix/metabolism ; Cell Culture Techniques ; Cell Line, Tumor
Abstract: Prostate cancer (PC) is the third most frequently diagnosed cancer worldwide and the second most frequent in men. Several risk factors can contribute to the development of PC, and those include age, family history, and specific genetic mutations. So far, drug testing in PC, as well as in cancer research in general, has been performed on 2D cell cultures. This is mainly because of the vast benefits these models provide, including simplicity and cost effectiveness. However, it is now known that these models are exposed to much higher stiffness; lose physiological extracellular matrix on artificial plastic surfaces; and show changes in differentiation, polarization, and cell-cell communication. This leads to the loss of crucial cellular signaling pathways and changes in cell responses to stimuli when compared to in vivo conditions. Here, we emphasize the importance of a diverse collection of 3D PC models and their benefits over 2D models in drug discovery and screening from the studies done so far, outlining their benefits and limitations. We highlight the differences between the diverse types of 3D models, with the focus on tumor-stroma interactions, cell populations, and extracellular matrix composition, and we summarize various standard and novel therapies tested on 3D models of PC for the purpose of raising awareness of the possibilities for a personalized approach in PC therapy.
References: Prostate. 2014 Feb;74(2):210-6. (PMID: 24132735)
Eur Urol Oncol. 2018 Sep;1(4):325-337. (PMID: 30467556)
Biomed Pharmacother. 2018 Nov;107:793-805. (PMID: 30142541)
J Clin Invest. 2023 Jan 17;133(2):. (PMID: 36647834)
Bioengineered. 2022 Feb;13(2):2710-2719. (PMID: 34738877)
Int J Mol Sci. 2021 May 01;22(9):. (PMID: 34062920)
Front Mol Biosci. 2020 Dec 01;7:609172. (PMID: 33335914)
Fam Cancer. 2022 Jan;21(1):101-114. (PMID: 33486571)
Bosn J Basic Med Sci. 2022 Jul 29;22(4):580-592. (PMID: 35694767)
Mol Cancer Res. 2020 Oct;18(10):1512-1521. (PMID: 32611550)
Biomaterials. 2009 Jun;30(16):3020-7. (PMID: 19304321)
Front Pharmacol. 2022 Feb 03;13:839620. (PMID: 35185589)
Pharmaceutics. 2023 Jan 11;15(1):. (PMID: 36678871)
Nat Rev Urol. 2018 Apr;15(4):222-234. (PMID: 29460925)
Nat Commun. 2023 Jan 17;14(1):252. (PMID: 36650183)
Braz J Med Biol Res. 2013 Jul;46(7):634-42. (PMID: 23903680)
Nutrients. 2018 Nov 16;10(11):. (PMID: 30453545)
Pathogens. 2022 Apr 21;11(5):. (PMID: 35631014)
FEBS Open Bio. 2018 Apr 17;8(5):817-828. (PMID: 29744295)
Avicenna J Med Biotechnol. 2022 Jan-Mar;14(1):89-94. (PMID: 35509367)
Mol Oncol. 2013 Apr;7(2):190-205. (PMID: 23481269)
Eur Urol. 2016 Jul;70(1):6-8. (PMID: 26850968)
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38. (PMID: 30131604)
Mo Med. 2018 Mar-Apr;115(2):156-161. (PMID: 30228709)
Cells. 2022 Apr 30;11(9):. (PMID: 35563823)
Radiology. 2021 Sep;300(3):594-604. (PMID: 34254851)
Front Mol Biosci. 2020 Jan 31;6:160. (PMID: 32118030)
J Exp Clin Cancer Res. 2020 Oct 8;39(1):213. (PMID: 33032653)
Am J Clin Exp Urol. 2022 Dec 25;10(6):366-376. (PMID: 36636693)
Mol Biol Rep. 2020 Nov;47(11):8727-8737. (PMID: 33085048)
Mol Oncol. 2018 Sep;12(9):1608-1622. (PMID: 30117261)
Cancer Invest. 2015;33(7):276-85. (PMID: 25951372)
Int J Mol Sci. 2022 Apr 05;23(7):. (PMID: 35409390)
PLoS One. 2021 Mar 4;16(3):e0246733. (PMID: 33661931)
Int J Oncol. 2014 Nov;45(5):1793-801. (PMID: 25120209)
Cancers (Basel). 2021 Feb 19;13(4):. (PMID: 33669619)
Molecules. 2020 Jun 16;25(12):. (PMID: 32560204)
Int J Clin Exp Pathol. 2013 Dec 15;7(1):184-93. (PMID: 24427338)
Clin Cancer Res. 2018 Sep 1;24(17):4332-4345. (PMID: 29748182)
Acta Pharmacol Sin. 2023 Jan 13;:. (PMID: 36639570)
Analyst. 2011 Feb 7;136(3):473-8. (PMID: 20967331)
Prostate Cancer Prostatic Dis. 2022 Nov 24;:. (PMID: 36434163)
Mol Cancer Ther. 2019 Feb;18(2):376-388. (PMID: 30478149)
Acta Biomater. 2021 Sep 15;132:360-378. (PMID: 33484910)
Oncol Rep. 2015 Mar;33(3):1388-94. (PMID: 25571882)
Eur Urol. 2021 Jan;79(1):150-158. (PMID: 32907777)
Cancers (Basel). 2020 Jul 28;12(8):. (PMID: 32731472)
Int J Mol Sci. 2020 Sep 16;21(18):. (PMID: 32948069)
J Vis Exp. 2011 May 06;(51):. (PMID: 21587162)
PLoS One. 2021 Jul 9;16(7):e0254315. (PMID: 34242345)
Biomaterials. 2015 Jun;52:347-57. (PMID: 25818441)
Sci Rep. 2021 Dec 1;11(1):23232. (PMID: 34853378)
Nat Commun. 2022 Nov 30;13(1):7367. (PMID: 36450752)
Am J Clin Exp Urol. 2017 Nov 09;5(3):25-33. (PMID: 29181435)
Life Sci. 2021 Aug 1;278:119554. (PMID: 33932444)
Int J Cancer. 2019 Sep 1;145(5):1382-1394. (PMID: 30828788)
Radiat Environ Biophys. 2018 May;57(2):133-142. (PMID: 29453555)
Res Rep Urol. 2022 Mar 30;14:87-108. (PMID: 35386270)
Oncotarget. 2019 Jan 22;10(7):749-759. (PMID: 30774777)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Nat Chem Biol. 2008 Nov;4(11):682-90. (PMID: 18936753)
Biomater Sci. 2021 Jan 5;9(1):133-147. (PMID: 33135714)
N Engl J Med. 2021 Sep 16;385(12):1091-1103. (PMID: 34161051)
PLoS Genet. 2020 Feb 14;16(2):e1008641. (PMID: 32059012)
Oncotarget. 2021 Jan 05;12(1):22-36. (PMID: 33456711)
J Clin Oncol. 2010 Sep 20;28(27):4247-54. (PMID: 20733135)
Oncol Rep. 2014 Aug;32(2):641-9. (PMID: 24927163)
Biopolymers. 2017 Feb;107(2):70-79. (PMID: 27696348)
Biomaterials. 2019 Mar;197:296-304. (PMID: 30682644)
Inorg Chem. 2022 Dec 5;61(48):19261-19273. (PMID: 36383699)
Ann Oncol. 2020 Sep;31(9):1119-1134. (PMID: 32593798)
Mol Cancer Res. 2018 Mar;16(3):453-460. (PMID: 29330287)
Prostate. 2010 Apr 1;70(5):491-501. (PMID: 19938015)
Biomaterials. 2019 Dec;223:119471. (PMID: 31525693)
Cancer Res. 2020 Mar 15;80(6):1268-1278. (PMID: 31941698)
J Clin Oncol. 2019 Nov 10;37(32):2974-2986. (PMID: 31329516)
Pharmaceuticals (Basel). 2021 Oct 04;14(10):. (PMID: 34681244)
J Nanobiotechnology. 2021 Mar 8;19(1):71. (PMID: 33685469)
Cells. 2021 Dec 22;11(1):. (PMID: 35011576)
Pharmaceutics. 2022 Apr 29;14(5):. (PMID: 35631550)
ACS Omega. 2016 Nov 30;1(5):952-962. (PMID: 27917408)
Biomed Pharmacother. 2023 Feb;158:114112. (PMID: 36508999)
BMC Cancer. 2018 May 24;18(1):592. (PMID: 29793440)
Cancers (Basel). 2023 Jan 11;15(2):. (PMID: 36672410)
Trends Cancer. 2021 Mar;7(3):249-264. (PMID: 33218948)
Cancers (Basel). 2022 Jul 31;14(15):. (PMID: 35954408)
Assay Drug Dev Technol. 2014 May;12(4):207-18. (PMID: 24831787)
Methods Mol Biol. 2018;1786:175-194. (PMID: 29786793)
Urology. 1999 Sep;54(3):523-7. (PMID: 10475365)
Int J Mol Sci. 2023 Jan 04;24(2):. (PMID: 36674430)
Prostate. 2012 Sep 15;72(13):1478-89. (PMID: 22396312)
Cancers (Basel). 2020 Jun 22;12(6):. (PMID: 32580291)
Biomaterials. 2014 Sep;35(27):7762-7773. (PMID: 24952981)
Sci Rep. 2019 Oct 18;9(1):15008. (PMID: 31628408)
Mol Carcinog. 2022 Mar;61(3):334-345. (PMID: 34818445)
Cancer Res. 2021 Dec 15;81(24):6207-6218. (PMID: 34753775)
Biomolecules. 2022 Dec 29;13(1):. (PMID: 36671452)
Biomacromolecules. 2015 May 11;16(5):1470-9. (PMID: 25857405)
J Cell Biol. 1997 Apr 7;137(1):231-45. (PMID: 9105051)
BJU Int. 2017 Jul;120(1):61-68. (PMID: 27743489)
Expert Opin Pharmacother. 2015;16(10):1521-37. (PMID: 26067250)
N Engl J Med. 2017 Jul 27;377(4):338-351. (PMID: 28578639)
Annu Rev Pathol. 2020 Jan 24;15:211-234. (PMID: 31550983)
N Engl J Med. 2020 Jun 4;382(23):2197-2206. (PMID: 32469184)
Am J Cancer Res. 2022 Mar 15;12(3):1116-1128. (PMID: 35411223)
Metabolites. 2022 Dec 31;13(1):. (PMID: 36676990)
Int J Mol Sci. 2020 Feb 13;21(4):. (PMID: 32070055)
Prostate. 2021 Jul;81(10):667-682. (PMID: 33956349)
Biotechnol Bioeng. 2002 Dec 5;80(5):580-8. (PMID: 12355469)
Chem Biol Drug Des. 2022 Nov;100(5):747-762. (PMID: 35775856)
Biomolecules. 2021 Oct 22;11(11):. (PMID: 34827570)
Semin Cancer Biol. 2005 Oct;15(5):405-12. (PMID: 16055341)
Mol Oncol. 2020 Oct;14(10):2487-2503. (PMID: 32579780)
J Toxicol Sci. 2021;46(11):515-523. (PMID: 34719554)
Med Oncol. 2022 Sep 7;39(12):194. (PMID: 36071289)
Cell. 2013 Apr 25;153(3):666-77. (PMID: 23622249)
Sci Rep. 2021 Mar 31;11(1):7290. (PMID: 33790399)
Cancers (Basel). 2022 Feb 11;14(4):. (PMID: 35205640)
Chemistry. 2021 Jun 10;27(33):8547-8556. (PMID: 33835526)
Science. 2014 Jul 18;345(6194):1247125. (PMID: 25035496)
Biotechnol Lett. 2005 Nov;27(21):1663-8. (PMID: 16247671)
Sci Rep. 2022 Aug 5;12(1):13508. (PMID: 35931743)
Curr Opin Urol. 2013 May;23(3):208-13. (PMID: 23492838)
N Engl J Med. 2022 Mar 24;386(12):1132-1142. (PMID: 35179323)
Int J Mol Sci. 2021 Dec 17;22(24):. (PMID: 34948357)
Onco Targets Ther. 2017 May 04;10:2427-2447. (PMID: 28496342)
Nat Biotechnol. 2014 Aug;32(8):760-72. (PMID: 25093883)
Bioeng Transl Med. 2021 Nov 17;7(2):e10266. (PMID: 35600657)
J Transl Med. 2012 Mar 06;10:38. (PMID: 22394685)
J Health Econ. 2003 Mar;22(2):151-85. (PMID: 12606142)
J BUON. 2014 Jan-Mar;19(1):207-14. (PMID: 24659666)
ACS Omega. 2022 Dec 29;8(1):56-73. (PMID: 36643505)
Clin Exp Pharmacol Physiol. 2021 Mar;48(3):422-434. (PMID: 33349973)
Nutr Res Pract. 2021 Feb;15(1):12-25. (PMID: 33542789)
J Vis Exp. 2022 Dec 16;(190):. (PMID: 36591992)
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):453-462. (PMID: 35790786)
J Immunother Cancer. 2021 Jun;9(6):. (PMID: 34088740)
Clinics (Sao Paulo). 2006 Oct;61(5):401-8. (PMID: 17072437)
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:465-472. (PMID: 27987733)
Front Cell Dev Biol. 2022 Feb 17;10:841017. (PMID: 35252204)
Mol Cell Biochem. 2020 Apr;467(1-2):45-56. (PMID: 32065351)
Cells. 2019 Feb 11;8(2):. (PMID: 30754655)
Nat Protoc. 2021 Jan;16(1):182-217. (PMID: 33247284)
Biomed Pharmacother. 2022 Jun;150:113031. (PMID: 35483199)
Cancer Res. 2013 May 1;73(9):2718-36. (PMID: 23610450)
ACS Appl Bio Mater. 2020 Aug 17;3(8):5093-5102. (PMID: 35021685)
FASEB J. 2020 Sep;34(9):11511-11528. (PMID: 32713076)
Med Oncol. 2021 Aug 7;38(9):112. (PMID: 34363546)
J Nutr Biochem. 2020 Oct;84:108444. (PMID: 32615369)
PLoS One. 2010 May 03;5(5):e10431. (PMID: 20454659)
Oncotarget. 2017 Apr 4;8(14):22741-22758. (PMID: 28009986)
Mol Carcinog. 2019 Jul;58(7):1105-1117. (PMID: 30828884)
Biotechnol Bioeng. 2001 Mar 20;72(6):579-91. (PMID: 11460249)
Drug Deliv. 2019 Dec;26(1):1115-1124. (PMID: 31735095)
BMC Urol. 2013 Jan 26;13:4. (PMID: 23351141)
Front Oncol. 2019 Aug 28;9:801. (PMID: 31555580)
Ann Oncol. 2017 Jul 01;28(7):1495-1507. (PMID: 28383660)
Oncotarget. 2019 Dec 03;10(64):6845-6854. (PMID: 31839878)
Cancer Cell. 2020 Aug 10;38(2):279-296.e9. (PMID: 32679108)
Int J Biochem Cell Biol. 2008;40(8):1443-51. (PMID: 18325824)
Tissue Eng Part C Methods. 2019 Aug;25(8):479-488. (PMID: 31328683)
Biotechnol Bioeng. 2019 Jan;116(1):206-226. (PMID: 30367820)
Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):604-9. (PMID: 12869398)
Prostate. 2020 Feb;80(2):113-132. (PMID: 31825540)
Biomed Res Int. 2022 Aug 24;2022:7626405. (PMID: 36060138)
N Engl J Med. 2020 May 28;382(22):2091-2102. (PMID: 32343890)
Int J Pharm. 2021 Sep 25;607:121018. (PMID: 34416329)
In Vitro Cell Dev Biol Anim. 2004 Sep-Oct;40(8-9):262-7. (PMID: 15723561)
Nat Commun. 2021 Feb 18;12(1):1117. (PMID: 33602919)
Cell Biosci. 2021 Nov 7;11(1):191. (PMID: 34743733)
Stem Cell Res Ther. 2022 May 7;13(1):188. (PMID: 35526071)
Int J Mol Sci. 2016 Sep 01;17(9):. (PMID: 27598125)
Pharmaceutics. 2023 Jan 11;15(1):. (PMID: 36678880)
Lancet Oncol. 2021 Nov;22(11):1618-1631. (PMID: 34678156)
Macromol Biosci. 2019 Jan;19(1):e1800249. (PMID: 30324687)
J Cancer Res Clin Oncol. 2012 Apr;138(4):675-86. (PMID: 22237455)
Methods Mol Biol. 2017;1612:167-175. (PMID: 28634942)
Front Oncol. 2022 May 24;12:877379. (PMID: 35686097)
Prostate Cancer Prostatic Dis. 2023 Mar;26(1):180-187. (PMID: 36401126)
Biotechnol Prog. 2003 Nov-Dec;19(6):1742-9. (PMID: 14656150)
Analyst. 2016 Aug 15;141(17):5056-61. (PMID: 27310732)
Biomed Res Int. 2021 May 22;2021:8859181. (PMID: 34095313)
Endocr Relat Cancer. 2022 Aug 17;29(10):R143-R155. (PMID: 35900853)
ACS Appl Bio Mater. 2021 May 17;4(5):4254-4270. (PMID: 35006838)
Mol Biol Rep. 2020 May;47(5):3691-3703. (PMID: 32246247)
Horm Cancer. 2020 Aug;11(3-4):182-190. (PMID: 32562083)
J Vis Exp. 2015 Oct 20;(105):53182. (PMID: 26555435)
Front Med (Lausanne). 2022 Sep 15;9:965429. (PMID: 36186774)
Drug Discov Today. 2013 Mar;18(5-6):240-9. (PMID: 23073387)
Front Oncol. 2022 Jul 13;12:943846. (PMID: 35912174)
Nat Rev Urol. 2013 Aug;10(8):483-7. (PMID: 23752995)
Clin Cancer Res. 2012 Jul 1;18(13):3562-70. (PMID: 22573351)
J Biomed Mater Res A. 2016 Jul;104(7):1591-602. (PMID: 26873510)
Transl Oncol. 2022 Sep 18;26:101543. (PMID: 36126563)
Exp Cell Res. 2012 Aug 1;318(13):1577-85. (PMID: 22487097)
Front Genet. 2022 Oct 11;13:911101. (PMID: 36303548)
Clin Pharmacol Ther. 2008 Feb;83(2):227-30. (PMID: 18202690)
Ups J Med Sci. 2006;111(3):293-301. (PMID: 17578796)
Cancers (Basel). 2022 Jul 09;14(14):. (PMID: 35884410)
Grant Information: Movember dm - drogerie markt d.o.o. donation
Contributed Indexing: Keywords: 3D models; prostate cancer; resistance; spheroids; therapy
Entry Date(s): Date Created: 20230329 Date Completed: 20230330 Latest Revision: 20230331
Update Code: 20230331
PubMed Central ID: PMC10049142
DOI: 10.3390/ijms24065293
PMID: 36982368
Database: MEDLINE
Full text is not displayed to guests.
Accede al texto completo
Description
ISSN:1422-0067
DOI:10.3390/ijms24065293